Objective: The few workloss studies of prostate cancer patients are short-term and single-treatment focused. We compare long-term patterns of workloss and costs of 5414 newly diagnosed patients over 10 years stratified by treatment type, age and risk group. Methods: Workloss patterns for prostate cancer were identified using CaPSURE, a national disease registry that includes clinical data and patient-reported outcome questionnaires, including demographics, co-morbidity, risk, and work patterns at 31 academic and community urology practices. Both change in work status (decreased if changed from full to part-time or disability, increased if changed back to full time, or no change) and hours lost were assessed at six-month intervals over ten years. National hourly wages were used to determine workloss costs by age, disease risk, and treatment type. Results: Patients reported average weekly work reductions of 15.7 hours in the first 6 month period resulting in $6310 in lost wages. This loss decreased in the 2nd 6 month period as 6.2% reported increasing work status, 88% stayed the same, and 5.2% reported additional decreases, which continued into the first half of year 2. Work loss then increased to 7% until 6 years post treatment when it slowly decreased. Hours of work loss and gain over 10 years resulted in a weighted cumulative average wage loss of $146,500. Those at moderate risk lost more wages than high or low risk patients. Most wages were lost by those receiving androgen deprivation therapy medications alone ($190,000), while those receiving cryotherapy had the lowest wage loss ($99,500). Radical prostatectomy treatment alone resulted in $142,100 lost wages over 10 years. Conclusion: The wages lost after treatment for prostate cancer are high. This is the first long-term look at prostate cancer workloss. Although most wage loss occurs in the first six months, substantial loss continues over the next ten years.